Innovent and Lilly jointly announce the approval of Tyvyt (sintilimab injection) by China NMPA in combination with chemotherapy as first-line treatment for oesophageal squamous cell carcinoma

Innovent Biologics

20 June 2022 -  Innovent Biologics and Eli Lilly today announced that the Center for Drug Evaluation of China's National Medical Products Administration has approved the supplemental new drug application for Tyvyt (sintilimab) in combination with cisplatin plus paclitaxel or cisplatin plus 5-fluorouracil chemotherapy for the first-line treatment of unresectable, locally advanced, recurrent or metastatic iesophageal squamous cell carcinoma.

Read Innovent Biologics press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , China